A phase II study of BIBW 2992 added to letrozole in patients with estrogen receptor positive hormone refractory metastatic breast cancer progressing on letrozole.

Trial Profile

A phase II study of BIBW 2992 added to letrozole in patients with estrogen receptor positive hormone refractory metastatic breast cancer progressing on letrozole.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2013

At a glance

  • Drugs Afatinib; Letrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Jul 2012 Planned number of patients changed from 30 to 40 as reported by European Clinical Trials Database.
    • 03 Mar 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top